SEC Form 4 · accession 0001193125-26-304786
Rapport Therapeutics, Inc. · RAPP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abraham Ceesay
Officer — Chief Executive Officer · Director
Period of report
Jul 14, 2026
Accepted (ET)
Jul 15, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002012593
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 14, 2026 | S | 5,481 | $39.7217 | D | 542,546 | D | |
| Common StockF3 | Jul 14, 2026 | S | 2,729 | $40.5724 | D | 539,817 | D | |
| Common StockF4 | holding | — | — | — | 81,729 | I | By Ceesay Family Irrevocable Trust | |
| Common StockF5 | holding | — | — | — | 20,729 | I | By Dorothy Ceesay Irrevocable Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.36 to $40.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.37 to $40.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F5Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.